

The Pharma Development Pipeline Sustainability Report™

Will this company deliver sufficiently to maintain success on the market?

An investigation by **Seifert**Research

The Pharma Development Pipeline Sustainability Report™

All rights reserved.

Author:

Wolfgang Seifert, MD, PMP, Clinical Pharmacologist

Description:

The report presents the results of analyses of development pipelines of pharma companies, which publish the composition of development pipelines on the web. Based upon the current status of the development pipeline and by the use of statistical methods, a prediction is made of the future output in terms of the number of first new launches over time.

Scope:

Most of the pharma companies listed in major industrial indexes.

Tool:

SR-Pharmline™

The tool provides options for the use of company specific success rates and development times for up to six independent user definable project clusters (like oncology projects, cardiovascular projects, new medical entities or line extension projects, to name but a few).

Data more specific for a company in question may be obtained from benchmarking organizations or programs focusing on development performances.

Source of information:

All input information is from public sources.

Interpretation of results:

Section 1 of the report reveals the current status of a company's development pipeline and the numerical output thereof. As an assumption, global average success rates were used.

Section 2 presents the above information in a diagram and calculates the output over time, using average median development times.

Section 3 interprets the results in terms of sustainability of the development pipeline. Note, that this term is absolutely depending on the company's business model and philosophy.

"Sustainability" in this sense is defined as overall performance in terms of future output,

- sufficient to maintain the current business model and
- reflecting steady-state conditions in a stable environment

Individual company analysis:

For individual company analyses using specific company performance data, please contact SeifertResearch.

The Pharma Development Pipeline Sustainability Report TM

Issued: April 2007

All rights reserved. © W.Seifert 2006-2007

Email: WSeifert@SeifertResearch.de

www.SeifertResearch.de

Terms and conditions, limitation of liability:

Scope

SeifertResearch offers methods and tools for predictions on the outcome of pharma processes which are solely based on the performance of these processes in the recent past. The proposition is that such performances will be likely to be continued into the near future, and that any measures changing these performances will immediately result in changed forecasts. The predictions are generated through the use of computerized models. Although such mathematical models can be suitable tools to forecast a future event from the past performance, such evolvments underlie a multitude of internal and external influences which are beyond control of SeifertResearch. Applying the methods and the tools offered and making use of the publications provided is totally in the responsibility of the user.

Service

This service is made available to accommodate the professional needs of the customer's business, but not for third party commercialization. Using services and tools by SeifertResearch requires agreement to comply with Terms and Conditions of this report and of the respective tools. If you do not agree with our Terms and Conditions, please do not use the services and tools.

SeifertResearch is pleased to make the described services available to customers, but reserves the right to terminate offering of new services any time and without notice.

The customer is strictly forbidden to use the services/results of SeifertResearch for commercial purposes without their written permission.

In the case of any contravention of the above clause, SeifertResearch reserves the right to cancel the contract immediately and to claim for compensation.

Limitation of Liability

SeifertResearch disclaims liability for any personal injury, property or other damages of any nature whatsoever, whether special, indirect, consequential or compensatory, directly or indirectly resulting from the tools, services or publications, use of concepts or applications, or reliance on the suggested instruments or strategies, even if SeifertResearch has been advised of the possibility of such damages.

SeifertResearch disclaims and makes no guarantee or warranty, expressed or implied, as to the accuracy or completeness of any information published in this report or the contained products, concepts or strategies and disclaims and makes no warranty that the information provided will fulfill any of the users' particular purposes or needs. SeifertResearch does not undertake to guarantee the adequateness and appropriateness of any result, product or service offered to the needs of the customer.

SeifertResearch does not accept any liability for factual or legal flaws in the contractual services provided.

Recommendation to Seek Additional Advice

Anyone using the reports, methods, tools or concepts provided should rely on his or her own independent judgment, or, as appropriate, seek the advice of a competent professional in determining the exercise of reasonable care in any given circumstances.

Information and other standards on the topic covered by this publication, services or tools may also be available from other sources, which the user is encouraged to consult for additional views or information not covered here.

Law and Jurisdiction

This notice will be governed by and construed in accordance with German law, and any disputes relating to this notice shall be subject to the exclusive jurisdiction of the legal domicile of Dr. Wolfgang Seifert, SeifertResearch, Berlin, Germany.

Contents:

Abbott Laboratories No data provided	CV Therapeutics → 25	NPS Pharmaceuticals → 44
Alexion → 5	Dainippon Pharmaceutical → 26	Onyx Pharmaceuticals → 45
Alkermes Inc. → 6	deCODE Genetics → 27	Organon → 46
Altus Pharmaceuticals → 7	Eisai Co. Ltd. → 28	Pfizer Inc. → 47
Amgen Inc. → 8	Elan PLC → 29	Protein Design Labs → 48
Amylin Pharmaceuticals → 9	Eli Lilly and Company Insufficient data	Rigel Pharmaceuticals → 49
Anadys Pharmaceuticals → 10	Enzon → 30	Sanofi Aventis → 50
Arena Pharmaceuticals → 11	Epix Pharmaceuticals → 31	Schering-Plough → 51
Ariad Pharmaceuticals → 12	F. Hoffmann-La Roche Ltd. → 32	Schwarz Pharma → 52
Arqule Inc. → 13	Genentech → 33	Sepracor Inc → 53
Array Biopharma Inc. → 14	Genzyme → 34	Shionogi → 54
AstraZeneca Plc → 15	Gilead Sciences → 35	Shire Pharm. → 55
Atherogenics → 16	GlaxoSmithKline → 36	Takeda Chemical Industries → 56
Biogen Idec → 17	Johnson&Johnson → 37	Tanabe Seiyaky → 57
Bristol-Myers Squibb Co. → 18	Lundbeck → 38	Telik → 58
Cancervax → 19	MedImmune Inc. → 39	Teva Pharmaceuticals → 59
Cell Genesys → 20	Merck&Co. → 40	UCB → 60
Cell Therapeutics → 21	Millennium Pharmaceuticals → 41	Watson Pharmaceuticals → 61
Cephalon Inc. → 22	Nektar → 42	Wyeth Corp. → 62
Chugai Pharmaceutical Co. Ltd. → 23	Novartis No data provided	Zymogenetics → 63
Corgentech-Anesiva → 24	NovoNordisk → 43	

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	7	0,63	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	3	2,85	1,20	0,60
Sums			10	3,48	9,00	

Overall percentage to reach the market: 34,80 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,87	#NV
50	1,74	08.06.07
75	2,61	12.08.08
90	3,13	01.07.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	2	0,18	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			5	1,22	9,00	

Overall percentage to reach the market: 24,40 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,31	14.09.08
50	0,61	23.04.10
75	0,92	16.10.12
90	1,10	15.06.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			4	1,58	9,00	

Overall percentage to reach the market: 39,50 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,40	16.03.08
50	0,79	04.05.09
75	1,19	24.11.10
90	1,42	01.03.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	15	1,95	1,30	6,95
PhII → PhIII	0,23	PhII	11	2,53	2,60	5,00
PhIII → Subm	0,68	PhIII	9	6,12	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			35	10,60	9,00	

Overall percentage to reach the market: 30,29 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	2,65	18.08.08
50	5,30	09.02.10
75	7,95	28.02.12
90	9,54	26.05.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	3	0,39	1,30	6,95
PhII → PhIII	0,23	PhII	3	0,69	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			8	2,44	9,00	

Overall percentage to reach the market: 30,50 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,61	29.08.08
50	1,22	22.02.10
75	1,83	27.02.12
90	2,20	23.04.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			4	0,58	9,00	

Overall percentage to reach the market: 14,50 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,15	05.02.11
50	0,29	21.11.12
75	0,44	29.11.14
90	0,52	25.11.16

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	3	0,27	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	3	2,04	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			8	2,67	9,00	

Overall percentage to reach the market: 33,38 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,67	02.05.08
50	1,34	03.08.09
75	2,00	12.05.11
90	2,40	19.01.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	6	0,54	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	3	0,69	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			10	1,36	9,00	

Overall percentage to reach the market: 13,60 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,34	16.01.11
50	0,68	08.12.12
75	1,02	15.02.15
90	1,22	10.04.17

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			3	0,49	9,00	

Overall percentage to reach the market: 16,33 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,12	09.11.10
50	0,25	25.07.12
75	0,37	17.06.14
90	0,44	15.04.16

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	2	0,18	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			5	0,67	9,00	

Overall percentage to reach the market: 13,40 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,17	20.04.11
50	0,34	21.02.13
75	0,50	18.03.15
90	0,60	24.03.17

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	49	4,41	1,40	8,30
PhI → PhII	0,13	PhI	21	2,73	1,30	6,95
PhII → PhIII	0,23	PhII	20	4,60	2,60	5,00
PhIII → Subm	0,68	PhIII	28	19,04	2,50	2,45
Subm → Launch	0,95	Subm	5	4,75	1,20	0,60
Sums			123	35,53	9,00	

Overall percentage to reach the market: 28,89 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	8,88	16.01.08
50	17,77	10.08.09
75	26,65	13.12.11
90	31,98	06.11.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			2	0,81	9,00	

Overall percentage to reach the market: 40,50 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,20	28.03.08
50	0,41	24.05.09
75	0,61	26.12.10
90	0,73	13.03.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	4	0,36	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	9	2,07	2,60	5,00
PhIII → Subm	0,68	PhIII	7	4,76	2,50	2,45
Subm → Launch	0,95	Subm	1	0,95	1,20	0,60
Sums			23	8,40	9,00	

Overall percentage to reach the market: 36,52 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	2,10	28.01.08
50	4,20	05.07.09
75	6,30	14.05.11
90	7,56	28.07.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	13	1,69	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	6	4,08	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			19	5,77	9,00	

Overall percentage to reach the market: 30,37 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,44	10.06.08
50	2,89	31.10.09
75	4,33	03.01.12
90	5,19	10.09.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	3	0,27	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			6	0,86	9,00	

Overall percentage to reach the market: 14,33 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,22	06.12.10
50	0,43	09.10.12
75	0,65	28.11.14
90	0,77	14.01.17

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			5	1,36	9,00	

Overall percentage to reach the market: 27,20 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,34	13.10.08
50	0,68	12.05.10
75	1,02	27.06.12
90	1,22	06.10.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			3	1,49	9,00	

Overall percentage to reach the market: 49,67 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,37	17.02.08
50	0,75	14.03.09
75	1,12	28.07.10
90	1,34	08.03.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	5	0,45	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	4	2,72	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			12	3,76	9,00	

Overall percentage to reach the market: 31,33 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,94	23.05.08
50	1,88	13.09.09
75	2,82	14.08.11
90	3,38	04.05.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	6	0,78	1,30	6,95
PhII → PhIII	0,23	PhII	13	2,99	2,60	5,00
PhIII → Subm	0,68	PhIII	7	4,76	2,50	2,45
Subm → Launch	0,95	Subm	10	9,50	1,20	0,60
Sums			36	18,03	9,00	

Overall percentage to reach the market: 50,08 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	4,51	#NV
50	9,02	16.01.08
75	13,52	19.12.09
90	16,23	07.05.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	4	0,92	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	1	0,95	1,20	0,60
Sums			8	2,81	9,00	

Overall percentage to reach the market: 35,13 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,70	26.06.07
50	1,41	05.03.09
75	2,11	24.08.11
90	2,53	11.11.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	3	0,27	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	4	2,72	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			10	3,58	9,00	

Overall percentage to reach the market: 35,80 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,90	01.05.08
50	1,79	27.07.09
75	2,69	26.03.11
90	3,22	24.08.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	13	2,99	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	3	2,85	1,20	0,60
Sums			19	7,33	9,00	

Overall percentage to reach the market: 38,58 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,83	06.05.07
50	3,67	17.12.08
75	5,50	20.05.11
90	6,60	08.06.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			4	1,27	9,00	

Overall percentage to reach the market: 31,75 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,32	06.09.08
50	0,64	24.02.10
75	0,95	26.01.12
90	1,14	30.01.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	5	0,65	1,30	6,95
PhII → PhIII	0,23	PhII	8	1,84	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	2	1,90	1,20	0,60
Sums			16	5,07	9,00	

Overall percentage to reach the market: 31,69 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,27	06.06.07
50	2,54	09.05.09
75	3,80	21.01.12
90	4,56	26.03.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction



Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	3	0,27	1,40	8,30
PhI → PhII	0,13	PhI	3	0,39	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	2	1,90	1,20	0,60
Sums			9	2,79	9,00	

Overall percentage to reach the market: 31,00 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages

Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,70	#NV
50	1,40	18.10.07
75	2,09	31.03.11
90	2,51	12.11.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	3	0,69	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			5	0,91	9,00	

Overall percentage to reach the market: 18,20 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,23	20.06.10
50	0,46	27.01.12
75	0,68	09.12.13
90	0,82	11.11.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	4	0,92	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			5	1,05	9,00	

Overall percentage to reach the market: 21,00 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,26	16.04.10
50	0,53	14.10.11
75	0,79	22.06.13
90	0,95	20.02.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	28	3,64	1,30	6,95
PhII → PhIII	0,23	PhII	24	5,52	2,60	5,00
PhIII → Subm	0,68	PhIII	36	24,48	2,50	2,45
Subm → Launch	0,95	Subm	6	5,70	1,20	0,60
Sums			94	39,34	9,00	

Overall percentage to reach the market: 41,85 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	9,84	15.11.07
50	19,67	15.03.09
75	29,51	19.12.10
90	35,41	28.01.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	4	0,36	1,40	8,30
PhI → PhII	0,13	PhI	12	1,56	1,30	6,95
PhII → PhIII	0,23	PhII	11	2,53	2,60	5,00
PhIII → Subm	0,68	PhIII	13	8,84	2,50	2,45
Subm → Launch	0,95	Subm	2	1,90	1,20	0,60
Sums			42	15,19	9,00	

Overall percentage to reach the market: 36,17 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	3,80	03.01.08
50	7,60	08.06.09
75	11,39	09.05.11
90	13,67	22.09.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	10	0,90	1,40	8,30
PhI → PhII	0,13	PhI	7	0,91	1,30	6,95
PhII → PhIII	0,23	PhII	8	1,84	2,60	5,00
PhIII → Subm	0,68	PhIII	9	6,12	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			34	9,77	9,00	

Overall percentage to reach the market: 28,74 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	2,44	19.07.08
50	4,89	28.12.09
75	7,33	11.02.12
90	8,79	18.09.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	1	0,95	1,20	0,60
Sums			6	2,86	9,00	

Overall percentage to reach the market: 47,67 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,72	14.05.07
50	1,43	07.08.08
75	2,15	09.05.10
90	2,57	29.05.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	39	5,07	1,30	6,95
PhII → PhIII	0,23	PhII	65	14,95	2,60	5,00
PhIII → Subm	0,68	PhIII	30	20,40	2,50	2,45
Subm → Launch	0,95	Subm	9	8,55	1,20	0,60
Sums			143	48,97	9,00	

Overall percentage to reach the market: 34,24 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	12,24	27.12.07
50	24,49	24.08.09
75	36,73	06.10.11
90	44,07	28.11.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	31	21,08	2,50	2,45
Subm → Launch	0,95	Subm	7	6,65	1,20	0,60
Sums			38	27,73	9,00	

Overall percentage to reach the market: 72,97 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	6,93	20.06.07
50	13,87	13.07.08
75	20,80	21.10.09
90	24,96	08.01.11

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	3	0,39	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	4	2,72	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			8	3,34	9,00	

Overall percentage to reach the market: 41,75 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,84	06.04.08
50	1,67	05.06.09
75	2,51	29.12.10
90	3,01	15.01.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	18	1,62	1,40	8,30
PhI → PhII	0,13	PhI	8	1,04	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			30	4,48	9,00	

Overall percentage to reach the market: 14,93 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,12	26.10.09
50	2,24	20.05.12
75	3,36	10.01.15
90	4,03	09.04.17

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	29	3,77	1,30	6,95
PhII → PhIII	0,23	PhII	20	4,60	2,60	5,00
PhIII → Subm	0,68	PhIII	5	3,40	2,50	2,45
Subm → Launch	0,95	Subm	3	2,85	1,20	0,60
Sums			57	14,62	9,00	

Overall percentage to reach the market: 25,65 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	3,66	16.03.08
50	7,31	11.06.10
75	10,97	20.11.12
90	13,16	21.01.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	3	0,27	1,40	8,30
PhI → PhII	0,13	PhI	3	0,39	1,30	6,95
PhII → PhIII	0,23	PhII	8	1,84	2,60	5,00
PhIII → Subm	0,68	PhIII	3	2,04	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			17	4,54	9,00	

Overall percentage to reach the market: 26,71 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,14	22.11.08
50	2,27	08.07.10
75	3,41	06.08.12
90	4,09	06.10.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	5	0,65	1,30	6,95
PhII → PhIII	0,23	PhII	5	1,15	2,60	5,00
PhIII → Subm	0,68	PhIII	3	2,04	2,50	2,45
Subm → Launch	0,95	Subm	2	1,90	1,20	0,60
Sums			15	5,74	9,00	

Overall percentage to reach the market: 38,27 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,44	08.06.07
50	2,87	25.11.08
75	4,31	26.02.11
90	5,17	29.07.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	5	0,65	1,30	6,95
PhII → PhIII	0,23	PhII	7	1,61	2,60	5,00
PhIII → Subm	0,68	PhIII	5	3,40	2,50	2,45
Subm → Launch	0,95	Subm	3	2,85	1,20	0,60
Sums			20	8,51	9,00	

Overall percentage to reach the market: 42,55 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	2,13	25.05.07
50	4,26	03.10.08
75	6,38	23.10.10
90	7,66	26.01.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	1	0,95	1,20	0,60
Sums			7	2,99	9,00	

Overall percentage to reach the market: 42,71 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,75	02.06.07
50	1,50	23.09.08
75	2,24	29.08.10
90	2,69	18.12.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	5	1,15	2,60	5,00
PhIII → Subm	0,68	PhIII	6	4,08	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			13	5,49	9,00	

Overall percentage to reach the market: 42,23 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,37	04.05.08
50	2,75	22.07.09
75	4,12	11.02.11
90	4,94	24.12.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	23	2,99	1,30	6,95
PhII → PhIII	0,23	PhII	12	2,76	2,60	5,00
PhIII → Subm	0,68	PhIII	6	4,08	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			41	9,83	9,00	

Overall percentage to reach the market: 23,98 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	2,46	22.01.09
50	4,92	11.11.10
75	7,37	10.02.13
90	8,85	29.03.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	49	6,37	1,30	6,95
PhII → PhIII	0,23	PhII	32	7,36	2,60	5,00
PhIII → Subm	0,68	PhIII	8	5,44	2,50	2,45
Subm → Launch	0,95	Subm	3	2,85	1,20	0,60
Sums			92	22,02	9,00	

Overall percentage to reach the market: 23,93 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	5,51	31.08.08
50	11,01	28.10.10
75	16,52	19.02.13
90	19,82	26.03.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	6	1,38	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			9	2,32	9,00	

Overall percentage to reach the market: 25,78 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,58	22.04.09
50	1,16	13.12.10
75	1,74	06.11.12
90	2,09	11.09.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	3	0,27	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	3	0,69	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			8	1,22	9,00	

Overall percentage to reach the market: 15,25 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,31	26.10.10
50	0,61	06.08.12
75	0,92	28.08.14
90	1,10	26.09.16

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	38	3,42	1,40	8,30
PhI → PhII	0,13	PhI	29	3,77	1,30	6,95
PhII → PhIII	0,23	PhII	33	7,59	2,60	5,00
PhIII → Subm	0,68	PhIII	25	17,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			125	31,78	9,00	

Overall percentage to reach the market: 25,42 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	7,95	26.09.08
50	15,89	04.05.10
75	23,84	05.09.12
90	28,60	03.03.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	11	2,53	2,60	5,00
PhIII → Subm	0,68	PhIII	14	9,52	2,50	2,45
Subm → Launch	0,95	Subm	4	3,80	1,20	0,60
Sums			29	15,85	9,00	

Overall percentage to reach the market: 54,66 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	3,96	23.07.07
50	7,93	14.10.08
75	11,89	25.04.10
90	14,27	05.01.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	3	0,39	1,30	6,95
PhII → PhIII	0,23	PhII	3	0,69	2,60	5,00
PhIII → Subm	0,68	PhIII	3	2,04	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			9	3,12	9,00	

Overall percentage to reach the market: 34,67 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,78	25.06.08
50	1,56	02.11.09
75	2,34	11.09.11
90	2,81	05.11.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			3	0,35	9,00	

Overall percentage to reach the market: 11,67 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,09	25.01.12
50	0,18	08.11.13
75	0,26	26.10.15
90	0,32	22.09.17

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	7	1,61	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	5	4,75	1,20	0,60
Sums			14	7,17	9,00	

Overall percentage to reach the market: 51,21 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,79	#NV
50	3,59	06.10.07
75	5,38	28.07.09
90	6,45	22.04.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	8	0,72	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	1	0,23	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	3	2,85	1,20	0,60
Sums			12	3,80	9,00	

Overall percentage to reach the market: 31,67 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,95	#NV
50	1,90	07.08.07
75	2,85	10.07.09
90	3,42	20.11.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	10	2,30	2,60	5,00
PhIII → Subm	0,68	PhIII	6	4,08	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			16	6,38	9,00	

Overall percentage to reach the market: 39,88 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,60	22.06.08
50	3,19	11.10.09
75	4,79	30.05.11
90	5,74	26.02.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	3	0,39	1,30	6,95
PhII → PhIII	0,23	PhII	5	1,15	2,60	5,00
PhIII → Subm	0,68	PhIII	1	0,68	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			9	2,22	9,00	

Overall percentage to reach the market: 24,67 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,56	23.04.09
50	1,11	04.01.11
75	1,67	28.12.12
90	2,00	05.12.14

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	3	0,27	1,40	8,30
PhI → PhII	0,13	PhI	1	0,13	1,30	6,95
PhII → PhIII	0,23	PhII	8	1,84	2,60	5,00
PhIII → Subm	0,68	PhIII	5	3,40	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			17	5,64	9,00	

Overall percentage to reach the market: 33,18 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	1,41	21.07.08
50	2,82	10.12.09
75	4,23	20.10.11
90	5,08	24.11.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	1	0,09	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	5	1,15	2,60	5,00
PhIII → Subm	0,68	PhIII	2	1,36	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			8	2,60	9,00	

Overall percentage to reach the market: 32,50 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,65	07.09.08
50	1,30	16.02.10
75	1,95	21.12.11
90	2,34	27.11.13

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	2	0,26	1,30	6,95
PhII → PhIII	0,23	PhII	6	1,38	2,60	5,00
PhIII → Subm	0,68	PhIII	5	3,40	2,50	2,45
Subm → Launch	0,95	Subm	4	3,80	1,20	0,60
Sums			17	8,84	9,00	

Overall percentage to reach the market: 52,00 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	2,21	#NV
50	4,42	03.04.08
75	6,63	01.02.10
90	7,96	27.02.12

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	0	0,00	2,60	5,00
PhIII → Subm	0,68	PhIII	3	2,04	2,50	2,45
Subm → Launch	0,95	Subm	0	0,00	1,20	0,60
Sums			3	2,04	9,00	

Overall percentage to reach the market: 68,00 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,51	08.01.08
50	1,02	10.01.09
75	1,53	27.02.10
90	1,84	12.04.11

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	0	0,00	1,30	6,95
PhII → PhIII	0,23	PhII	14	3,22	2,60	5,00
PhIII → Subm	0,68	PhIII	18	12,24	2,50	2,45
Subm → Launch	0,95	Subm	6	5,70	1,20	0,60
Sums			38	21,16	9,00	

Overall percentage to reach the market: 55,68 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	5,29	26.06.07
50	10,58	11.09.08
75	15,87	23.03.10
90	19,04	11.12.11

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.

Date of Analysis: 1-Apr-07

Section 1: Current status and numerical prediction

Average Pharma Probability of Launch		Current projects, future output and phase duration				
Transition	pLaunch	currently (4.2007) in	actual number of processed projects	Predicted number to reach the market	average median duration (yy)	Cumulated median duration (yy); current phase /2
Prec → PhI	0,09	Preclin	0	0,00	1,40	8,30
PhI → PhII	0,13	PhI	9	1,17	1,30	6,95
PhII → PhIII	0,23	PhII	2	0,46	2,60	5,00
PhIII → Subm	0,68	PhIII	0	0,00	2,50	2,45
Subm → Launch	0,95	Subm	1	0,95	1,20	0,60
Sums			12	2,58	9,00	

Overall percentage to reach the market: 21,50 %

Section 2: Prediction over time

Diagram 1: Projects in and output from development stages





Diagram 2: Prediction of spread of output over time



Section 3: Assumption on sustainability

Table 1: Characteristics of launches from current pipeline

Percentage launched:	Number of products	By date
25	0,65	08.08.07
50	1,29	18.11.10
75	1,94	09.09.13
90	2,32	10.11.15

Half of the median development time is currently assumed to be 4.5 years. A pipeline launched by 50% in less than half of the median development time following the date of analysis is not considered to be sustainable.